Skip to content
PreclinicalResearch compound

DHB (Dihydroboldenone)

Injectable muscle-building steroid never approved as a medicine; no human studies exist and it is banned in sport.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DHB (Dihydroboldenone) vial

DETAILED OVERVIEW

What is DHB (Dihydroboldenone)?

DHB (Dihydroboldenone, also known as 1-Testosterone) is an anabolic, meaning muscle-building, steroid and a close relative of the steroid boldenone. It has never been an approved medicine, either for humans or for animals, and exists only on the black market, as an injection. In the European Union, including Hungary and Poland, it is a controlled substance that is illegal without a prescription, and in competitive sport it is banned all year round.

Unlike boldenone, it does not turn into estrogen, and it puts little strain on the liver. It has strong male-hormone effects: it can cause acne and faster hair loss, worsens cholesterol values, raises blood pressure, and suppresses the body's own testosterone production, which leads to shrinking testicles and fertility problems. It is notorious for pain and swelling at the injection site that last for days. No human study has been done with it, and its effects are inferred from related drugs, so its long-term safety is unknown. In women it causes partly irreversible masculinization, and it must not be used in pregnancy.

Mechanism

AR agonist, 1-Testosterone (Δ1-DHT), NOT aromatized

Anabolic:Androgenic

200:100

Half-life

8-10 days (Cypionate ester)

Onset

48-72 h (IM)

Legal status

UGL only, no Rx approval. WADA-banned.

Data console

Lab data

Androgenic:Anabolic200:100
AR bindingHigh AR affinity (~200% vs testosterone in vitro…
Active half-life~24-36 h (depot-driven, free 1-testosterone after hydrolysis)
Detection windowDHB metabolites (1-androstene-3,17-dione + 1-testosterone metabolite family) urinary 6-9 months (extra long detection due to Cypionate ester, USADA designer-steroid-alert data). WADA-accredited LC-MS/MS.
AromatizationNo – 5α-reduced structure, NOT a CYP19 substrate; the parent Boldenone aromatizes, but DHB is already reduced → clinically no E2 elevation expected (Pope-Kanayama 2014 PMID 24423981 designer AAS review, extrapolated Boldenone-Methenolone data)
HepatotoxicityLow – parent steroid, NOT 17α-alkylated; injected form bypasses first-pass. Hepatic profile similar to Masteron-Primobolan class (extrapolated, DHB-specific peer-reviewed data missing; Hartgens-Kuipers 2004 PMID 15233599 c17-non-AA injectable AAS class data).

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Severe post-injection pain (PIP): DHB is notorious for extreme local swelling and aseptic inflammation lasting 3-5 days, often preventing training of the injected muscle.
  • Strong androgenic effects: oily skin, acne, and accelerated male-pattern hair loss in those genetically predisposed (DHT-structural analog; finasteride does NOT protect as it is already 5a-reduced).
  • Adverse lipid profile: significant HDL drop (around 20-30%) and LDL rise; more cumulative than Masteron/Primobolan due to high androgenic activity – cardiovascular risk.
  • HPTA suppression: shutdown of endogenous testosterone (LH/FSH), testicular atrophy, reduced libido and fertility; PCT (Clomid + Nolvadex) needed for recovery.
  • Elevated blood pressure and possible rise in hematocrit/red blood cell count (AAS class effect), increasing thrombosis and cardiovascular strain risk.
  • Prostate stimulation: high androgenic activity can promote prostate enlargement and aggravate pre-existing prostate conditions.
  • Unknown long-term safety: a designer AAS never clinically tested – pharmacology is extrapolated from the Boldenone/Methenolone class, so rare or serious effects cannot be excluded.

Contraindications · 7

  • Female use: risk of virilization (deepened voice, hirsutism, clitoral enlargement) is extreme and partly irreversible – absolutely contraindicated.
  • Pregnancy and breastfeeding: teratogenic/virilizing to the fetus – absolutely contraindicated.
  • Prostate or breast carcinoma, or prostate hypertrophy: androgenic stimulation may worsen these – contraindicated.
  • Existing cardiovascular disease, uncontrolled hypertension, or adverse lipids (LDL >130 / HDL <40 mg/dL): contraindicated due to HDL suppression and blood pressure rise.
  • Androgenetic alopecia (family/personal history): high androgenic activity accelerates hair loss and finasteride offers no protection – strongly contraindicated.
  • Anticoagulant therapy (e.g. warfarin): AAS can potentiate the anticoagulant effect – contraindicated without INR monitoring.
  • First-cycle or inexperienced users: DHB is never a standalone entry AAS; not advisable for beginners due to severe PIP and unknown safety profile.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about DHB (Dihydroboldenone)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.